Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Navigation/Suche

• Forscher*innen.
• Institutionen.
• Projekte.
• Publikationen.
• Partner.
• Geldgeber.
• Ausstattung.
• Knowhow.
• Forschungsfelder.

Publikationen

Suchbegriffe: TAMOXIFEN, . Treffer: 45

2022

Behringer, A; Stoimenovski, D; Porsch, M; Hoffmann, K; Behre, G; Grosse, I; Kalinski, T; Haybaeck, J; Nass, N Relationship of micro-RNA, mRNA and eIF Expression in Tamoxifen-Adapted MCF-7 Breast Cancer Cells: Impact of miR-1972 on Gene Expression, Proliferation and Migration.
Biomolecules. 2022; 12(7): Doi: 10.3390/biom12070916 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Czapiewski, P; Cornelius, M; Hartig, R; Kalinski, T; Haybaeck, J; Dittmer, A; Dittmer, J; Ignatov, A; Nass, N BCL3 expression is strongly associated with the occurrence of breast cancer relapse under tamoxifen treatment in a retrospective cohort study.
Virchows Arch. 2022; Doi: 10.1007/s00428-021-03238-8 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Graf, S; Haybaeck, J; Behre, G; Kalinski, T; Nass, N The tamoxifen-regulated, long non-coding RNA LINC00992 affects proliferation, migration, and expression of tamoxifen resistance-associated genes in MCF-7 breast cancer cells.
Contemp Oncol (Pozn). 2022; 26(4): 294-305. Doi: 10.5114/wo.2023.125000 [OPEN ACCESS]
PubMed FullText FullText_MUG

 

2021

Fitzal, F; Filipits, M; Fesl, C; Rudas, M; Greil, R; Balic, M; Moinfar, F; Herz, W; Dubsky, P; Bartsch, R; Ferree, S; Schaper, C; Gnant, M; Austrian Breast and Colorectal Cancer Study Group (ABCSG) PAM-50 predicts local recurrence after breast cancer surgery in postmenopausal patients with ER+/HER2- disease: results from 1204 patients in the randomized ABCSG-8 trial.
Br J Surg. 2021; 108(3): 308-314. Doi: 10.1093/bjs/znaa089 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Mofarrah, R; Mofarrah, R; Kränke, B; Rahmani, M; Jahani Amiri, K; Ghasemi, M; Jallab, N; Ghobadiaski, S; Rahmani, N; Hashemi, N First report of tamoxifen-induced baboon syndrome.
J Cosmet Dermatol. 2020; Doi: 10.1111/jocd.13863 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2020

Bago-Horvath, Z; Rudas, M; Singer, CF; Greil, R; Balic, M; Lax, SF; Kwasny, W; Hulla, W; Gnant, M; Filipits, M Predictive Value of Molecular Subtypes in Premenopausal Women with Hormone Receptor-positive Early Breast Cancer: Results from the ABCSG Trial 5.
Clin Cancer Res. 2020; 26(21): 5682-5688. Doi: 10.1158/1078-0432.CCR-20-0673
Web of Science PubMed FullText FullText_MUG

 

2019

Ignatov, T; Claus, M; Nass, N; Haybaeck, J; Seifert, B; Kalinski, T; Ortmann, O; Ignatov, A G-protein-coupled estrogen receptor GPER-1 expression in hormone receptor-positive breast cancer is associated with poor benefit of tamoxifen.
Breast Cancer Res Treat. 2019; 174(1):121-127 Doi: 10.1007/s10549-018-5064-8
Web of Science PubMed FullText FullText_MUG

 

Porsch, M; Özdemir, E; Wisniewski, M; Graf, S; Bull, F; Hoffmann, K; Ignatov, A; Haybaeck, J; Grosse, I; Kalinski, T; Nass, N Time resolved gene expression analysis during tamoxifen adaption of MCF-7 cells identifies long non-coding RNAs with prognostic impact.
RNA Biol. 2019; 16(5):661-674 Doi: 10.1080/15476286.2019.1581597 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2018

Schochter, F; Rack, B; Tzschaschel, M; Polasik, A; Andergassen, U; Trapp, E; Alunni-Fabbroni, M; Schneeweiss, A; Müller, V; Pantel, K; Gade, J; Lorenz, R; Rezai, M; Tesch, H; Soeling, U; Fehm, T; Mahner, S; Schindlbeck, C; Lichtenegger, W; Beckmann, MW; Fasching, PA; Janni, W; Friedl, TWP; SUCCESS Study Group Endocrine Treatment with 2 Years of Tamoxifen versus 2 Years of Exemestane in Postmenopausal Patients with High-Risk Early Breast Cancer and Persisting Circulating Tumor Cells - First Results of the SUCCESS C Endocrine Treatment Sub-Study.
Oncol Res Treat. 2018; 41(3):93-98 Doi: 10.1159/000485566 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2017

Gruber, R; Rogerson, C; Windpassinger, C; Banushi, B; Straatman-Iwanowska, A; Hanley, J; Forneris, F; Strohal, R; Ulz, P; Crumrine, D; Menon, GK; Blunder, S; Schmuth, M; Müller, T; Smith, H; Mills, K; Kroisel, P; Janecke, AR; Gissen, P Autosomal Recessive Keratoderma-Ichthyosis-Deafness (ARKID) Syndrome Is Caused by VPS33B Mutations Affecting Rab Protein Interaction and Collagen Modification.
J Invest Dermatol. 2017; 137(4):845-854 Doi: 10.1016/j.jid.2016.12.010 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2016

Rasoulzadeh, Z; Ghods, R; Kazemi, T; Mirzadegan, E; Ghaffari-Tabrizi-Wizsy, N; Rezania, S; Kazemnejad, S; Arefi, S; Ghasemi, J; Vafaei, S; Mahmoudi, AR; Zarnani, AH Placental Kisspeptins Differentially Modulate Vital Parameters of Estrogen Receptor-Positive and -Negative Breast Cancer Cells.
PLoS One. 2016; 11(4):e0153684-e0153684 Doi: 10.1371/journal.pone.0153684 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2015

Fitzal, F; Filipits, M; Rudas, M; Greil, R; Dietze, O; Samonigg, H; Lax, S; Herz, W; Dubsky, P; Bartsch, R; Kronenwett, R; Gnant, M The genomic expression test EndoPredict is a prognostic tool for identifying risk of local recurrence in postmenopausal endocrine receptor-positive, her2neu-negative breast cancer patients randomised within the prospective ABCSG 8 trial.
Br J Cancer. 2015; 112(8):1405-1410 Doi: 10.1038/bjc.2015.98 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Gnant, M; Mlineritsch, B; Stoeger, H; Luschin-Ebengreuth, G; Knauer, M; Moik, M; Jakesz, R; Seifert, M; Taucher, S; Bjelic-Radisic, V; Balic, M; Eidtmann, H; Eiermann, W; Steger, G; Kwasny, W; Dubsky, P; Selim, U; Fitzal, F; Hochreiner, G; Wette, V; Sevelda, P; Ploner, F; Bartsch, R; Fesl, C; Greil, R; Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12.
Ann Oncol. 2015; 26(2):313-320 Doi: 10.1093/annonc/mdu544 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Gnant, M; Sestak, I; Filipits, M; Dowsett, M; Balic, M; Lopez-Knowles, E; Greil, R; Dubsky, P; Stoeger, H; Rudas, M; Jakesz, R; Ferree, S; Cowens, JW; Nielsen, T; Schaper, C; Fesl, C; Cuzick, J Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype.
Ann Oncol. 2015; 26(8):1685-1691 Doi: 10.1093/annonc/mdv215 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2014

Gnant, M; Filipits, M; Greil, R; Stoeger, H; Rudas, M; Bago-Horvath, Z; Mlineritsch, B; Kwasny, W; Knauer, M; Singer, C; Jakesz, R; Dubsky, P; Fitzal, F; Bartsch, R; Steger, G; Balic, M; Ressler, S; Cowens, JW; Storhoff, J; Ferree, S; Schaper, C; Liu, S; Fesl, C; Nielsen, TO; Austrian Breast and Colorectal Cancer Study Group Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone.
Ann Oncol. 2014; 25(2):339-345 Doi: 10.1093/annonc/mdt494 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Province, MA; Goetz, MP; Brauch, H; Flockhart, DA; Hebert, JM; Whaley, R; Suman, VJ; Schroth, W; Winter, S; Zembutsu, H; Mushiroda, T; Newman, WG; Lee, MT; Ambrosone, CB; Beckmann, MW; Choi, JY; Dieudonné, AS; Fasching, PA; Ferraldeschi, R; Gong, L; Haschke-Becher, E; Howell, A; Jordan, LB; Hamann, U; Kiyotani, K; Krippl, P; Lambrechts, D; Latif, A; Langsenlehner, U; Lorizio, W; Neven, P; Nguyen, AT; Park, BW; Purdie, CA; Quinlan, P; Renner, W; Schmidt, M; Schwab, M; Shin, JG; Stingl, JC; Wegman, P; Wingren, S; Wu, AH; Ziv, E; Zirpoli, G; Thompson, AM; Jordan, VC; Nakamura, Y; Altman, RB; Ames, MM; Weinshilboum, RM; Eichelbaum, M; Ingle, JN; Klein, TE; International Tamoxifen Pharmacogenomics Consortium CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations.
Clin Pharmacol Ther. 2014; 95(2):216-227 Doi: 10.1038/clpt.2013.186 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Winder, T; Giamas, G; Wilson, PM; Zhang, W; Yang, D; Bohanes, P; Ning, Y; Gerger, A; Stebbing, J; Lenz, HJ Insulin-like growth factor receptor polymorphism defines clinical outcome in estrogen receptor-positive breast cancer patients treated with tamoxifen.
Pharmacogenomics J. 2014; 14(1):28-34 Doi: 10.1038/tpj.2013.8
Web of Science PubMed FullText FullText_MUG

 

2013

Paetzold, S; Gary, T; Hafner, F; Brodmann, M Thrombosis of the inferior vena cava related to Ormond's disease.
Clin Rheumatol. 2013; 32 Suppl 1(3): S67-S70. Doi: 10.1007/s10067-010-1456-9 (- Case Report)
Web of Science PubMed FullText FullText_MUG

 

Pfeiler, G; Stöger, H; Dubsky, P; Mlineritsch, B; Singer, C; Balic, M; Fitzal, F; Moik, M; Kwasny, W; Selim, U; Renner, K; Ploner, F; Steger, GG; Seifert, M; Hofbauer, F; Sandbichler, P; Samonigg, H; Jakesz, R; Greil, R; Fesl, C; Gnant, M; ABCSG Efficacy of tamoxifen ± aminoglutethimide in normal weight and overweight postmenopausal patients with hormone receptor-positive breast cancer: an analysis of 1509 patients of the ABCSG-06 trial.
Br J Cancer. 2013; 108(7):1408-1414 Doi: 10.1038/bjc.2013.114 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2012

Dubsky, PC; Jakesz, R; Mlineritsch, B; Pöstlberger, S; Samonigg, H; Kwasny, W; Tausch, C; Stöger, H; Haider, K; Fitzal, F; Singer, CF; Stierer, M; Sevelda, P; Luschin-Ebengreuth, G; Taucher, S; Rudas, M; Bartsch, R; Steger, GG; Greil, R; Filipcic, L; Gnant, M Tamoxifen and anastrozole as a sequencing strategy: a randomized controlled trial in postmenopausal patients with endocrine-responsive early breast cancer from the Austrian Breast and Colorectal Cancer Study Group.
J Clin Oncol. 2012; 30(7):722-728 Doi: 10.1200/JCO.2011.36.8993 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2011

Gnant, M; Mlineritsch, B; Stoeger, H; Luschin-Ebengreuth, G; Heck, D; Menzel, C; Jakesz, R; Seifert, M; Hubalek, M; Pristauz, G; Bauernhofer, T; Eidtmann, H; Eiermann, W; Steger, G; Kwasny, W; Dubsky, P; Hochreiner, G; Forsthuber, EP; Fesl, C; Greil, R; Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.
Lancet Oncol. 2011; 12(7):631-641 Doi: 10.1016/S1470-2045(11)70122-X
Web of Science PubMed FullText FullText_MUG

 

Parmar, S; Stingl, JC; Huber-Wechselberger, A; Kainz, A; Renner, W; Langsenlehner, U; Krippl, P; Brockmöller, J; Haschke-Becher, E Impact of UGT2B7 His268Tyr polymorphism on the outcome of adjuvant epirubicin treatment in breast cancer.
Breast Cancer Res. 2011; 13(3):R57-R57 Doi: 10.1186/bcr2894 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Pfeiler, G; Königsberg, R; Fesl, C; Mlineritsch, B; Stoeger, H; Singer, CF; Pöstlberger, S; Steger, GG; Seifert, M; Dubsky, P; Taucher, S; Samonigg, H; Bjelic-Radisic, V; Greil, R; Marth, C; Gnant, M Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial.
J Clin Oncol. 2011; 29(19):2653-2659 Doi: 10.1200/JCO.2010.33.2585 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

 

2008

Fink, D; Lang, U; Kimmig, R Fundamental advances in the adjuvant systemic therapy of breast cancer
Gynakol Geburtshilfliche Rundsch. 2008; 48(3):111-112 Doi: 10.1159/000127391
PubMed FullText FullText_MUG

 

2007

Gnant, MF; Mlineritsch, B; Luschin-Ebengreuth, G; Grampp, S; Kaessmann, H; Schmid, M; Menzel, C; Piswanger-Soelkner, JC; Galid, A; Mittlboeck, M; Hausmaninger, H; Jakesz, R; Austrian Breast and Colorectal Cancer Study Group Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group.
J Clin Oncol. 2007; 25(7): 820-828. Doi: 10.1200/JCO.2005.02.7102 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Jakesz, R; Greil, R; Gnant, M; Schmid, M; Kwasny, W; Kubista, E; Mineritsch, B; Tausch, C; Stierer, M; Hofbauer, F; Renner, K; Dadak, C; Ruecklinger, E; Samonigg, H Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a.
J Natl Cancer Inst. 2007; 99(24):1845-1853 Doi: 10.1093/jnci/djm246 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

 

Moinfar, F; Azodi, M; Tavassoli, FA Uterine sarcomas.
PATHOLOGY. 2007; 39(1): 55-71. Doi: 10.1080/00313020601136146
Web of Science PubMed FullText FullText_MUG

 

Pötter, R; Gnant, M; Kwasny, W; Tausch, C; Handl-Zeller, L; Pakisch, B; Taucher, S; Hammer, J; Luschin-Ebengreuth, G; Schmid, M; Sedlmayer, F; Stierer, M; Reiner, G; Kapp, K; Hofbauer, F; Rottenfusser, A; Pöstlberger, S; Haider, K; Draxler, W; Jakesz, R; Austrian Breast and Colorectal Cancer Study Group Lumpectomy plus tamoxifen or anastrozole with or without whole breast irradiation in women with favorable early breast cancer.
INT J RADIAT ONCOL BIOL PHYS. 2007; 68(2): 334-340. Doi: 10.1016/j.ijrobp.2006.12.045
Web of Science PubMed FullText FullText_MUG

 

Reich, O; Regauer, S Hormonal therapy of endometrial stromal sarcoma.
Curr Opin Oncol. 2007; 19(4):347-352 Doi: 10.1097/CCO.0b013e3281a7ef3a
Web of Science PubMed FullText FullText_MUG

 

2006

Reich, O; Regauer, S Survey of adjuvant hormone therapy in patients after endometrial stromal sarcoma.
Eur J Gynaecol Oncol. 2006; 27(2):150-152
Web of Science PubMed

 

Schirmer, M; Duftner, C; Seiler, R; Dejaco, C; Fraedrich, G Abdominal aortic aneurysms: an underestimated type of immune-mediated large vessel arteritis?
Curr Opin Rheumatol. 2006; 18(1): 48-53. Doi: 10.1097/01.bor.0000198001.35203.36
Web of Science PubMed FullText FullText_MUG

 

2005

Jakesz, R; Jonat, W; Gnant, M; Mittlboeck, M; Greil, R; Tausch, C; Hilfrich, J; Kwasny, W; Menzel, C; Samonigg, H; Seifert, M; Gademann, G; Kaufmann, M Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial.
Lancet. 2005; 366(9484):455-462 Doi: 10.1016/S0140-6736(05)67059-6 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

 

2004

Lackner, H; Urban, C; Benesch, M; Raith, J; Moser, A; Sovinz, P; Schwinger, W; Dornbusch, HJ; Triebl-Roth, K Multimodal treatment of children with unresectable or recurrent desmoid tumors: an 11-year longitudinal observational study.
J Pediatr Hematol Oncol. 2004; 26(8):518-522 Doi: 10.1097/01.mph.0000130219.26284.b3 (- Case Report)
Web of Science PubMed FullText FullText_MUG Google Scholar

 

2003

Pohl, G; Rudas, M; Dietze, O; Lax, S; Markis, E; Pirker, R; Zielinski, CC; Hausmaninger, H; Kubista, E; Samonigg, H; Jakesz, R; Filipits, M High p27Kip1 expression predicts superior relapse-free and overall survival for premenopausal women with early-stage breast cancer receiving adjuvant treatment with tamoxifen plus goserelin.
J Clin Oncol. 2003; 21(19):3594-3600 Doi: 10.1200/JCO.2003.02.021 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

 

Schmid, M; Jakesz, R; Samonigg, H; Kubista, E; Gnant, M; Menzel, C; Seifert, M; Haider, K; Taucher, S; Mlineritsch, B; Steindorfer, P; Kwasny, W; Stierer, M; Tausch, C; Fridrik, M; Wette, V; Steger, G; Hausmaninger, H Randomized trial of tamoxifen versus tamoxifen plus aminoglutethimide as adjuvant treatment in postmenopausal breast cancer patients with hormone receptor-positive disease: Austrian breast and colorectal cancer study group trial 6.
J Clin Oncol. 2003; 21(6):984-990 Doi: 10.1200/JCO.2003.01.138 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

 

2002

Jakesz, R; Hausmaninger, H; Kubista, E; Gnant, M; Menzel, C; Bauernhofer, T; Seifert, M; Haider, K; Mlineritsch, B; Steindorfer, P; Kwasny, W; Fridrik, M; Steger, G; Wette, V; Samonigg, H; Austrian Breast and Colorectal Cancer Study Group Trial 5 Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer--Austrian Breast and Colorectal Cancer Study Group Trial 5.
J CLIN ONCOL 2002 20: 4621-4627. Doi: 10.1200%2FJCO.2002.09.112 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

 

Jakesz, R; Hausmaninger, H; Samonigg, H Chemotherapy versus hormonal adjuvant treatment in premenopausal patients with breast cancer.
Eur J Cancer. 2002; 38(3):327-332 Doi: 10.1016%2FS0959-8049%2801%2900375-6
Web of Science PubMed FullText FullText_MUG Google Scholar

 

Kollroser, M; Schober, C Determination of amiodarone and desethylamiodarone in human plasma by high-performance liquid chromatography-electrospray ionization tandem mass spectrometry with an ion trap detector.
J Chromatogr B Analyt Technol Biomed Life Sci. 2002; 766(2):219-226 Doi: 10.1016/S0378-4347(01)00469-8
Web of Science PubMed FullText FullText_MUG

 

1999

Kucera, E; Speiser, P; Gnant, M; Szabo, L; Samonigg, H; Hausmaninger, H; Mittlböck, M; Fridrik, M; Seifert, M; Kubista, E; Reiner, A; Zeillinger, R; Jakesz, R Prognostic significance of mutations in the p53 gene, particularly in the zinc-binding domains, in lymph node- and steroid receptor positive breast cancer patients. Austrian Breast Cancer Study Group.
Eur J Cancer. 1999; 35(3):398-405 Doi: 10.1016/S0959-8049(98)00400-6
Web of Science PubMed FullText FullText_MUG Google Scholar

 

Villunger, A; Ghaffari-Tabrizi, N; Tinhofer, I; Krumböck, N; Bauer, B; Schneider, T; Kasibhatla, S; Greil, R; Baier-Bitterlich, G; Uberall, F; Green, DR; Baier, G Synergistic action of protein kinase C theta and calcineurin is sufficient for Fas ligand expression and induction of a crmA-sensitive apoptosis pathway in Jurkat T cells.
Eur J Immunol. 1999; 29(11):3549-3561 Doi: 10.1002/(SICI)1521-4141(199911)29:11<3549::AID-IMMU3549>3.0.CO;2-Q
Web of Science PubMed FullText FullText_MUG

 

1997

Lackner, H; Urban, C; Kerbl, R; Schwinger, W; Beham, A Noncytotoxic drug therapy in children with unresectable desmoid tumors.
Cancer. 1997; 80(2):334-340 Doi: 10.1002%2F%28SICI%291097-0142%2819970715%2980%3A2%3C334%3A%3AAID-CNCR22%3E3.0.CO%3B2-U (- Case Report) [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

 

1996

Bauernhofer, T; Stöger, H; Schmid, M; Smola, M; Gürtl-Lackner, B; Höfler, G; Ranner, G; Reisinger, E; Samonigg, H Sequential treatment of recurrent mesenteric desmoid tumor.
Cancer. 1996; 77(6):1061-1065 Doi: 10.1002/(SICI)1097-0142(19960315)77:6<1061::AID-CNCR9>3.0.CO;2-K (- Case Report) [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

1993

Fink-Puches, R; Helige, C; Kerl, H; Smolle, J; Tritthart, HA Inhibition of melanoma cell directional migration in vitro via different cellular targets.
Exp Dermatol. 1993; 2(1):17-24 Doi: 10.1111/j.1600-0625.1993.tb00194.x
PubMed FullText FullText_MUG Google Scholar

 

Ofner, D; Hittmair, A; Marth, C; Tötsch, M; Daxenbichler, G; Margreiter, R; Böcker, W; Schmid, KW Relationship between quantity of silver stained nucleolar organizer region associated proteins (Ag-NORs) and growth rate suppression of breast cancer cell lines after interferon-gamma and 4-hydroxy-tamoxifen treatment.
Virchows Arch B Cell Pathol Incl Mol Pathol. 1993; 63(6):359-363 Doi: 10.1007/BF02899284
Web of Science PubMed FullText FullText_MUG

 

Petru, E; Lahousen, M; Urdl, W; Luschin, G; Pickel, H Hormone substitution in patients after primary treatment of gynecologic malignancies
Wien Med Wochenschr. 1993; 143(21): 539-541.
PubMed

 

↑ Seitenanfang / Navigation

© Med Uni Graz • Impressum